=Progenics Pharm (PGNX) reported earnings on Thur 4 May 2017 (b/o)

Progenics Pharm misses by $0.04, misses on revs :

• Reports Q1 (Mar) loss of $0.23 per share, $0.04 worse than the Capital IQ Consensus of ($0.19); revenues fell 4.0% year/year to $2.4 mln vs the $4.5 mln Capital IQ Consensus.
• Phase 3 Study of 1404 Remains On-Track; Phase 2 Data Published in the Journal of Nuclear Medicine. Progenics continues to enroll patients in a Phase 3 study of 1404. The trial is designed to evaluate the specificity of the imaging agent in identifying patients without clinically significant prostate cancer as well as its sensitivity to identify patients with clinically significant disease, and will include approximately 450 patients. Progenics still expects to complete enrollment by the end of 2017.